ABBV vs RHHBY Stock Comparison: AI Score, Valuation, Performance and Upside
AbbVie and Roche Holding are both large global pharmaceutical companies, but AbbVie concentrates on biopharmaceuticals spanning immunology, oncology, and neuroscience primarily in the United States market, while Roche combines pharmaceuticals with a substantial diagnostics business across a broader global geographic footprint.
AbbVie offers exposure to a successfully diversified immunology-led biopharmaceutical portfolio with a strong dividend track record, while Roche offers exposure to a unique combination of global pharmaceuticals and diagnostics. Consider whether you prefer AbbVie's immunology and dividend focus or Roche's diversified pharma-diagnostics global model.
ABBV and RHHBY are closely matched — they split the tracked metrics evenly. RHHBY has delivered stronger 1-year price return (+32.69% vs +21.05%), though ABBV has the better forward P/E setup (15.69x vs 16.29x for RHHBY). ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +8.26% for ABBV and +9.96% for RHHBY.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a diversified biopharmaceutical company that has successfully navigated a major patent cliff transition
- Believe newer immunology drug launches will continue driving revenue growth
- Value a long track record of consistent dividend payments and increases
- Prefer a portfolio concentrated on biopharmaceuticals over a combined pharma-diagnostics model
- Want exposure to a unique combination of pharmaceutical and diagnostics businesses
- Value the diversified global geographic revenue footprint beyond reliance on any single region
- Believe long-standing oncology leadership provides durable competitive advantages
- Are comfortable with the complexity of valuing a diversified pharma-diagnostics conglomerate
| Metric | ABBV | RHHBY |
|---|---|---|
| AI scorei | 53.2 | N/A |
| AI ranki | #346 | N/A |
| Latest closei | $256.46 | $54.97 |
| 1M returni | +4.17% | -2.55% |
| 6M returni | +10.38% | +4.65% |
| 1Y returni | +21.05% | +32.69% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | RHHBY |
|---|---|---|
| 1Y ago | $12.04K (+20.4%) started 2025-09-04 | $13.69K (+36.9%) started 2025-09-04 |
| 5Y ago | $31.74K (+217.4%) started 2021-09-07 | $15.81K (+58.1%) started 2021-09-07 |
| 10Y ago | $89.96K (+799.6%) started 2016-09-06 | $35.8K (+258.0%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | RHHBY |
|---|---|---|
| Market capi | $451.46B | $350.39B |
| Trailing P/Ei | 71.97 | 23.29 |
| Forward P/Ei | 15.69 | 16.29 |
| Price/Salesi | 5.85 | 5.57 |
| EV/Revenuei | 8.01 | 6.00 |
| Analyst targeti | $276.59 | $60.44 |
| Target upsidei | +8.26% | +9.96% |
| Metric | ABBV | RHHBY |
|---|---|---|
| Revenue growthi | 10.20% | -1.20% |
| Earnings growthi | 290.40% | -7.70% |
| EPS growthi | +290.40% | -7.70% |
| FCF margini | +26.20% | +16.39% |
| Operating margini | 40.03% | 36.20% |
| Profit margini | 9.80% | 19.60% |
| ROIC proxyi | 6225.00% | 38.11% |
| Return on equityi | 6225.00% | 38.11% |
| Dividend yieldi | 2.71% | 2.82% |
| Betai | 0.28 | 0.35 |
| Debt/equityi | 4789.60 | 90.72 |
| Current ratioi | 0.81 | 1.23 |
| Quick ratioi | 0.49 | 0.80 |
Over the past year, ABBV and RHHBY have moved moderately in the same direction (correlation of 0.41), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | RHHBY |
|---|---|---|---|
| 1Y | Growthi | +20.40% | +32.69% |
| CAGRi | +20.44% | +32.71% | |
| Volatilityi | 26.52% | 29.11% | |
| Sharpe ratioi | 0.66 | 0.96 | |
| Sortino ratioi | 1.03 | 1.56 | |
| Max drawdowni | 19.23% | 19.30% | |
| Current drawdowni | 3.58% | 6.39% | |
| Avg drawdowni | 7.56% | 6.82% | |
| Ulcer Indexi | 8.96% | 8.94% | |
| Max daily dropi | 5.20% | 6.34% | |
| Max wkly dropi | 8.49% | 9.20% | |
| 5Y | Growthi | +171.75% | +32.27% |
| CAGRi | +22.17% | +5.76% | |
| Volatilityi | 23.36% | 24.02% | |
| Sharpe ratioi | 0.79 | 0.17 | |
| Sortino ratioi | 1.10 | 0.24 | |
| Max drawdowni | 21.92% | 40.81% | |
| Current drawdowni | 3.58% | 6.39% | |
| Avg drawdowni | 8.03% | 19.15% | |
| Ulcer Indexi | 9.97% | 21.95% | |
| Max daily dropi | 12.57% | 9.10% | |
| Max wkly dropi | 17.30% | 12.61% | |
| 10Y | Growthi | +475.40% | +144.38% |
| CAGRi | +19.14% | +9.35% | |
| Volatilityi | 26.00% | 22.84% | |
| Sharpe ratioi | 0.63 | 0.31 | |
| Sortino ratioi | 0.88 | 0.45 | |
| Max drawdowni | 45.09% | 40.81% | |
| Current drawdowni | 3.58% | 6.39% | |
| Avg drawdowni | 11.54% | 12.74% | |
| Ulcer Indexi | 15.57% | 16.52% | |
| Max daily dropi | 16.25% | 9.10% | |
| Max wkly dropi | 19.39% | 17.24% |
| Category | ABBV | RHHBY |
|---|---|---|
| Company | AbbVie Inc. | Roche Holding AG |
| Sector | Healthcare | Biotechnology |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | A biopharmaceutical company with a diversified portfolio spanning immunology, oncology, neuroscience, and aesthetics, having successfully transitioned its revenue base following the loss of patent exclusivity on its former flagship immunology drug. | A global healthcare company combining pharmaceutical and diagnostics businesses, with a broad portfolio spanning oncology, immunology, neuroscience, and diagnostic testing products and services worldwide. |
| Investor focus | Newer immunology drug growth trends replacing the prior flagship treatment, oncology and neuroscience pipeline contributions, and overall revenue diversification progress. | Oncology and immunology pharmaceutical pipeline progress, diagnostics division revenue trends, and overall geographic revenue diversification across global markets. |
- Successfully launched newer immunology drugs that have replaced much of the revenue lost from prior patent expiration
- Diversified therapeutic area exposure spans immunology, oncology, neuroscience, and aesthetics, reducing reliance on any single franchise
- Long track record of consistent dividend payments and increases supports its appeal among income-focused investors
- Unique combination of pharmaceutical and diagnostics businesses provides diversified revenue streams and cross-business insights
- Broad global geographic footprint diversifies revenue across international markets beyond reliance on any single region
- Long-standing leadership position in oncology treatment provides deep expertise and physician relationships worldwide
- Continued reliance on successful execution of newer immunology drug launches to fully offset prior patent cliff impact
- Competitive immunology therapeutic landscape includes numerous other well-resourced biopharmaceutical companies
- Aesthetics segment demand can be more discretionary and sensitive to broader consumer spending conditions
- Diversified conglomerate structure spanning pharmaceuticals and diagnostics can make it harder for investors to isolate individual segment performance
- Certain legacy pharmaceutical products face biosimilar and generic competition as patent exclusivity periods expire
- Currency fluctuations affect reported results given the company's substantial international revenue exposure
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.